Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
Alberto Juan, Alberto Ocaña(Hospital General Universitario de Albacete)
Cited by 37
Related Papers
Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
|Molecular Cancer Therapeutics|2017|63
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
|BMC Cancer|2014|58
Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer
|Oncotarget|2015|24
Considerations for the clinical development of immuno-oncology agents in cancer
|Frontiers in Immunology|2023|3